Delayed treatment with W1-mAb, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice

Critical Care Medicine

Volumn 39, Issue 6, 2011, Pages 1439-1447

  Altaweel, Laith ^a   Chen, Zhaochun ^b   Moayeri, Mahtab ^c   Cui, Xizhong ^a   Li, Yan ^a   Su, Junwu ^a   Fitz, Yvonne ^a   Johnson, Syd ^d   Leppla, Stephen H ^c   Purcell, Robert ^b   Eichacker, Peter Q ^a  

^a Clinical Center   (United States)

^b Laboratories of Infectious Diseases   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Analytical Sciences   (United States)

Author keywords

Bacillus anthracis; lethal and edema toxins; protective antigen directed mAb; rodent; treatment

Indexed keywords

EDEMA TOXIN; LETHAL TOXIN; MONOCLONAL ANTIBODY; PLACEBO; TOXIN; UNCLASSIFIED DRUG; W 1 MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CHIMPANZEE; CONTROLLED STUDY; DEATH; HEART RATE; HYPOTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

EID: 79957660251     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182120691     Document Type: Article

References (31)

1. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287: 863-868. (Pubitemid 34252033)
2. Holty JE, Bravata DM, Liu H, et al. Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-280. (Pubitemid 46768211)
3. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-944. (Pubitemid 33115771)
4. Klempner MS, Talbot EA, Lee SI, et al. Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock N Engl J Med 2010; 363:766-777.
5. Ramsay CN, Stirling A, Smith J, et al. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill 2010; 15:pii: 19465.
6. Pezard C, Berche P, Mock M: Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 1991; 59: 3472-3477.
7. Elliott JL, Mogridge J, Collier RJ: A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000; 39:6706-6713. (Pubitemid 30354003)
8. Mogridge J, Cunningham K, Collier RJ: Stoichiometry of anthrax toxin complexes. Biochemistry 2002; 41:1079-1082. (Pubitemid 34065284)
9. Duesbery NS, Vande Woude GF: Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase. J Appl Microbiol 1999; 87:289-293. (Pubitemid 29430343)
10. Ho DT, Bardwell AJ, Abdollahi M, et al. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 2003; 278:32662-32672. (Pubitemid 37055705)
11. Rainey GJ, Young JA: Antitoxins: Novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004; 2:721-726. (Pubitemid 39200063)
12. Vitale G, Pellizzari R, Recchi C, et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 1998; 248:706-711. (Pubitemid 28404486)
13. Leppla SH: Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982; 79: 3162-3166. (Pubitemid 12008374)
14. Cui X, Li Y, Moayeri M, et al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005; 191:422-434. (Pubitemid 40139768)
15. Sweeney DA, Cui X, Solomon SB, et al. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J Infect Dis 2010; 202:1885-1896.
16. Chen Z, Moayeri M, Crown D, et al. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with antiprotective antigen antibody. Infect Immun 2009; 77:3902-3908.
17. Cui X, Li Y, Li X, et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007; 195:572-580. (Pubitemid 46214400)
18. Cui X, Moayeri M, Li Y, et al. Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am J Physiol Regul Integr Comp Physiol 2004; 286:R699-R709. (Pubitemid 38375001)
19. Hu H, Sa Q, Koehler TM, et al. Inactivation of Bacillus anthracis spores in murine primary macrophages. Cell Microbiol 2006; 8:1634-1642. (Pubitemid 44350022)
20. Pomerantsev AP, Sitaraman R, Galloway CR, et al. Genome engineering in Bacillus anthracis using Cre recombinase. Infect Immun 2006; 74:682-693. (Pubitemid 43023124)
21. Chen Z, Moayeri M, Zhou YH, et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 2006; 193: 625-633. (Pubitemid 43271496)
22. DiFrancesco D, Tortora P: Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991; 351:145-147. (Pubitemid 21896552)
23. Murray KJ: Cyclic AMP and mechanisms of vasodilation. Pharmacol Ther 1990; 47: 329-345. (Pubitemid 20309555)
24. Lips DJ, Bueno OF, Wilkins BJ, et al. MEK1- ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 2004; 109:1938-1941. (Pubitemid 38544482)
25. Moayeri M, Crown D, Dorward DW, et al. The heart is an early target of anthrax lethal toxin in mice: A protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog 2009; 5:e1000456.
26. Purcell NH, Wilkins BJ, York A, et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 2007; 104: 14074-14079. (Pubitemid 350003337)
27. Warfel JM, Steele AD, D'Agnillo F: Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005; 166: 1871-1881. (Pubitemid 40734409)
28. Yamaguchi O, Watanabe T, Nishida K, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004; 114:937-943. (Pubitemid 39578721)
29. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361: 135-144.
30. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: Clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968-971. (Pubitemid 46452063)
31. Ehrlich PH, Moustafa ZA, Harfeldt KE, et al. Potential of primate monoclonal antibodies to substitute for human antibodies: Nucleotide sequence of chimpanzee Fab fragments. Hum Antibodies Hybridomas 1990; 1:23-26 (Pubitemid 20320599)